The societal burden of chronic liver diseases: results from the COME study-Reference-Cited by-同舟云学术

The societal burden of chronic liver diseases: results from the COME study

Published:2015-12-31 Issue:1 Volume:2 Page:e000025
ISSN:2054-4774
Container-title:BMJ Open Gastroenterology
language:en
Short-container-title:BMJ Open Gastroenterol

Author:

Scalone Luciana,Fagiuoli Stefano,Ciampichini Roberta,Gardini Ivan,Bruno Raffaele,Pasulo Luisa,Lucà Maria Grazia,Fusco Francesco,Gaeta Laura,Del Prete Anna,Cesana Giancarlo,Mantovani Lorenzo Giovanni

Publisher

BMJ

Subject

Gastroenterology

Reference33 articles.

1. European Centre for Disease Prevention and Control. Hepatitis B and Cin the EU neighborhood: prevalence, burden of disease and screening policies. 2010.

2. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis B

3. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide

4. NIH Consensus Statement on Management of hepatitis C: 2002;NIH Consens State Sci Statements,2002

5. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Pilot Study to Evaluate a New Hep-GRP Care Pathway to Improve Outcomes Among Canadian Older Adults with Liver Cirrhosis;Canadian Geriatrics Journal;2024-03-04

2. Toward Transplantation of Liver Organoids: From Biology and Ethics to Cost-effective Therapy;Transplantation;2023-07-20

3. Cost-effectiveness of selective internal radiation therapy with Y-90 resin microspheres for intermediate- and advanced-stage hepatocellular carcinoma in Brazil;Journal of Medical Economics;2023-05-24

4. The need for a risk-assessment tool among patients with chronic liver diseases interested in intermittent fasting: Ramadan model;Nutrition Reviews;2023-05-12

5. Three-dimensional mapping of hepatic lymphatic vessels and transcriptome profiling of lymphatic endothelial cells in healthy and diseased livers;Theranostics;2023